Variantyx Brings The First Combined Short- And Long-Read Whole Genome Sequencing Test To Market With Genomic Unity 2.0

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leading molecular diagnostics lab, today announced the launch of Genomic Unity^® 2.0, a novel whole genome-based diagnostic test. This advanced test integrates traditional short-read genome sequencing with third-generation long-read genome sequencing, detecting genetic variants that are missed by other methodologies and improving diagnostic yield.

Christine Stanley, PhD, FACMG, Chief Genomics & Compliance Officer at Variantyx, commented, “Genomic Unity^® 2.0 represents a significant advancement in genomic testing. Our laboratory has a longstanding history of excellence in genome analysis. With this new test, we are the first to incorporate third-generation long-read Oxford Nanopore sequencing alongside short-read sequencing in a clinical diagnostic context. This integration aims to improve sensitivity for detecting structural variants, enhance resolution in non-uniquely mappable regions, and analyze more short tandem repeats genes identifying over 44 repeat expansions.”

Dr. Stanley further noted, “Genomic Unity^® 2.0 also offers additional features, including the ability to provide methylation status and resolve variant phasing. These capabilities contribute to improved diagnostic accuracy and efficiency, while also reducing overall costs.”

Variantyx is committed to advancing the field of molecular diagnostics through continuous innovation. Genomic Unity^® 2.0 represents a key development in the company’s efforts to deliver more comprehensive and precise genomic insights.

For additional information on Genomic Unity^® 2.0 and its applications, please visit www.variantyx.com.

About Variantyx:

Variantyx is an award-winning, technology-driven molecular diagnostics lab that offers innovative solutions in the genetic disorders, reproductive health, and precision oncology markets. Our proprietary whole genome analysis platform provides unparalleled diagnostic capabilities, enhances personalized treatment recommendations, shortens the time to diagnosis, and reduces healthcare costs. For more information, please visit www.variantyx.com.

Contacts

Haim Neerman
Haim.neerman@variantyx.com
(617) 209-2090